Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EPS (Weighted Average and Diluted) (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed EPS (Weighted Average and Diluted) for 7 consecutive years, with $0.39 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 54.12% to $0.39 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.72 through Dec 2025, up 8.37% year-over-year, with the annual reading at $2.71 for FY2025, 7.97% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $0.39 in Q4 2025 for Harmony Biosciences Holdings, down from $0.87 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.44 in Q3 2022 to a low of -$0.17 in Q3 2021.
  • Historically, EPS (Weighted Average and Diluted) has averaged $0.55 across 5 years, with a median of $0.52 in 2023.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 77.25% in 2021 and later skyrocketed 947.06% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.38 in 2021, then surged by 107.89% to $0.79 in 2022, then tumbled by 43.04% to $0.45 in 2023, then skyrocketed by 88.89% to $0.85 in 2024, then tumbled by 54.12% to $0.39 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for HRMY at $0.39 in Q4 2025, $0.87 in Q3 2025, and $0.68 in Q2 2025.